Literature DB >> 8877934

The natural history of chronic pain in the community: a better prognosis than in the clinic?

G J MacFarlane1, E Thomas, A C Papageorgiou, J Schollum, P R Croft, A J Silman.   

Abstract

OBJECTIVE: To evaluate the predictors of improvement at 2 years in subjects with chronic widespread pain ascertained from a community survey.
METHODS: As part of a community based epidemiological survey on the occurrence of pain, 141 subjects (age range 24-74 years; 44 men, 97 women) were selected for more detailed assessment. Followup information on pain experience was collected at a median of 27 months (range 15-35). Subjects were categorized according to whether they had no pain, chronic widespread pain (according to the American College of Rheumatology criteria), or regional pain, both at initial assessment and followup. In addition, subjects were examined at both time periods for tender points.
RESULTS: Of those with chronic widespread pain at initial assessment, 35% still had chronic widespread pain at followup, 50% regional pain, and 15% no pain. Of those originally with regional pain, 65% still had regional pain, 19% chronic widespread pain, and 16% no pain at followup. Logistic regression analysis was conducted to examine factors among those with chronic widespread pain associated with still having these symptoms at followup. Female sex, older age, leaving school at a young age, high tender point count, high levels of fatigue, or additional physical or psychological symptoms were all associated with symptoms being less likely to resolve.
CONCLUSION: Chronic widespread pain in the community has a generally good prognosis. However, those with additional symptoms associated with the fibromyalgia syndrome were more likely still to have chronic widespread pain 2 years later.

Entities:  

Mesh:

Year:  1996        PMID: 8877934

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  31 in total

Review 1.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

2.  Understanding fibromyalgia and its related disorders.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  [Definition, classification and diagnosis of fibromyalgia syndrome].

Authors:  W Eich; W Häuser; E Friedel; A Klement; M Herrmann; F Petzke; M Offenbächer; M Schiltenwolf; C Sommer; T Tölle; P Henningsen
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

Review 4.  Chronic widespread pain and fibromyalgia: Should reports of increased mortality influence management?

Authors:  Gary J Macfarlane
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

Review 5.  Fibromyalgia: from pathophysiology to therapy.

Authors:  Tobias Schmidt-Wilcke; Daniel J Clauw
Journal:  Nat Rev Rheumatol       Date:  2011-07-19       Impact factor: 20.543

6.  Individuals with fibromyalgia and depression: findings from a nationally representative Canadian survey.

Authors:  Esme Fuller-Thomson; Jodie Nimigon-Young; Sarah Brennenstuhl
Journal:  Rheumatol Int       Date:  2011-01-08       Impact factor: 2.631

7.  Health-related quality of life, health risk behaviors, and disability among adults with pain-related activity difficulty.

Authors:  Tara W Strine; Jennifer M Hootman; Daniel P Chapman; Catherine A Okoro; Lina Balluz
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

8.  Intravenous lidocaine for fibromyalgia syndrome: an open trial.

Authors:  Marcelo Derbli Schafranski; Tiago Malucelli; Fabíola Machado; Hélcio Takeshi; Flávia Kaiber; Carolina Schmidt; Fabielle Harth
Journal:  Clin Rheumatol       Date:  2009-03-05       Impact factor: 2.980

Review 9.  Management of psychiatric comorbidity in fibromyalgia.

Authors:  Lesley M Arnold
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

Review 10.  Fibromyalgia: A Critical and Comprehensive Review.

Authors:  Andrea T Borchers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.